Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Translational research: Phase I study of niraparib and pimitespib in solid tumors (ancillary biomarker study)
jRCT1030220300Phase 1Active, not recruiting
- Sponsor
- Yoichi Naito
- Start
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of niraparib and pimitespib in Nonhematologic neoplasms, sponsored by Yoichi Naito. Primary endpoints: Correlation of objective response rate with biomarkers and Correlation of disease control rate with biomarkers. Started Aug 2022; status: active, not recruiting.
02
Drugs
niraparibpimitespib
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on jRCT1030220300.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1030220300.